(NASDAQ: PYXS) Pyxis Oncology's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.36%.
Pyxis Oncology's earnings in 2026 is -$81,735,000.On average, 10 Wall Street analysts forecast PYXS's earnings for 2026 to be -$79,891,263, with the lowest PYXS earnings forecast at -$93,753,442, and the highest PYXS earnings forecast at -$72,510,349. On average, 10 Wall Street analysts forecast PYXS's earnings for 2027 to be -$78,757,200, with the lowest PYXS earnings forecast at -$104,929,349, and the highest PYXS earnings forecast at -$54,549,070.
In 2028, PYXS is forecast to generate -$78,598,811 in earnings, with the lowest earnings forecast at -$122,934,977 and the highest earnings forecast at -$29,270,233.